The DOI matches its Crossref record.
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aggregation-Induced Emission: Together We Shine, United We Soar!
Mei, J., Leung, N. L. C., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00263 · Cited by 8,270
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Block copolymer micelles for drug delivery: Design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.013 · Cited by 783
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Metal-organic frameworks as potential drug delivery systems
Sun, C.-Y., Qin, C., Wang, X.-L., & Su, Z.-M. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.741583 · Cited by 408
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells
Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042803.28024.92 · Cited by 317
Platinum(iv) anticancer prodrugs – hypotheses and facts
Gibson, D. (2016) · Dalton Transactions · doi:10.1039/c6dt01414c · Cited by 286
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies
El-Awady, E.-S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.085 · Cited by 260
Nishiyama, N., Yokoyama, M., Aoyagi, T., Okano, T., Sakurai, Y., & Kataoka, K. (1999) · Langmuir · doi:10.1021/la980572l · Cited by 259
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Folate-decorated nanogels for targeted therapy of ovarian cancer
Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V., & Bronich, T. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.006 · Cited by 223
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Skinner, R. (2018) · Pediatric Nephrology · doi:10.1007/s00467-017-3662-z · Cited by 67
Metadata
- Authors
- Pinzani, V., Bressolle, F., Johanne Haug, I., Galtier, M., Blayac, J. P., & Balm�s, P.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1994
- Volume
- 35
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2079571567
- Cited by
- 217
- References
- 0
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.